Claudin-12 Deficiency Inhibits Tumor Growth by Impairing Transendothelial Migration of Myeloid-Derived Suppressor Cells.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
05 07 2022
Historique:
received: 14 11 2021
revised: 23 02 2022
accepted: 13 05 2022
pubmed: 18 5 2022
medline: 8 7 2022
entrez: 17 5 2022
Statut: ppublish

Résumé

Migration of myeloid-derived suppressor cells (MDSC) out of the circulation, across vascular walls, and into tumor is crucial for their immunosuppressive activity. A deeper understanding of critical junctional molecules and the regulatory mechanisms that mediate the extravasation of MDSCs could identify approaches to overcome cancer immunosuppression. In this study, we used mice deficient in tight junction protein Claudin-12 (Cldn12) compared with wild-type mice and found that loss of host Cldn12 inhibited the growth of transplanted tumors, reduced intratumoral accumulation of MDSCs, increased antitumor immune responses, and decreased tumor vascular density. Further studies revealed that Cldn12 expression on the cell surface of both MDSCs and endothelial cells (EC) is required for MDSCs transit across tumor vascular ECs. Importantly, expression of Cldn12 in MDSCs was modulated by GM-CSF in an AKT-dependent manner. Therefore, our results indicate that Cldn12 could serve as a promising target for restoring the antitumor response by interfering with MDSCs transendothelial migration. Claudin-12-mediated homotypic interactions are critical for migration of myeloid-derived suppressor cells across vascular walls into tumor tissue, providing a potential therapeutic approach to overcome cancer immunosuppression.

Identifiants

pubmed: 35580275
pii: 698996
doi: 10.1158/0008-5472.CAN-21-3896
doi:

Substances chimiques

Claudins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2472-2484

Informations de copyright

©2022 American Association for Cancer Research.

Auteurs

Hong Cao (H)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.

Chen Ni (C)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Le Han (L)

Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.

Ruoqi Wang (R)

Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.

Rosel Blasig (R)

Department of Molecular Cell Physiology, Leibniz Institute of Molecular Pharmacology, Berlin, Germany.

Reiner Haseloff (R)

Department of Molecular Cell Physiology, Leibniz Institute of Molecular Pharmacology, Berlin, Germany.

Yue Qin (Y)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.

Jie Lan (J)

Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.

Xiaohan Lou (X)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Pan Ma (P)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.

Xiaohan Yao (X)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Linlin Wang (L)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Fei Wang (F)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Linyu Zhu (L)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Ningjing Lei (N)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Ingolf E Blasig (IE)

Department of Molecular Cell Physiology, Leibniz Institute of Molecular Pharmacology, Berlin, Germany.

Zhihai Qin (Z)

Medical Research Center, Henan China--Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH